Factors determining final height in congenital adrenal hyperplasia

J Pediatr Endocrinol Metab. 2001 Jul:14 Suppl 2:933-7. doi: 10.1515/jpem-2001-s204.

Abstract

Congenital adrenal hyperplasia (CAH) is a family of adrenal disorders whereby cortisol biosynthesis is impaired or abolished. In most cases, CAH is caused by a deficiency of the enzyme 21-hydroxylase causing a massive build up of adrenal precursors. In addition to prenatal virilisation of genetic females and postnatal virilisation of both males and females, short adult stature is characteristic of the disorder. The inadequate final height in CAH patients is often attributed to overtreatment with glucocorticoid replacement and poor control of adrenal androgen levels. In a recent study, the use of growth hormone alone and in combination with gonadotropin releasing hormone analogue in children with CAH and poor predicted final height was found to decrease height deficit after one and two years of treatment.

Publication types

  • Guideline
  • Review

MeSH terms

  • Adrenal Hyperplasia, Congenital / drug therapy
  • Adrenal Hyperplasia, Congenital / genetics
  • Adrenal Hyperplasia, Congenital / physiopathology*
  • Body Height / drug effects
  • Body Height / genetics
  • Body Height / physiology*
  • Female
  • Humans
  • Infant, Newborn
  • Male